Search Results - "Diabetes Mellitus, Type 2 drug therapy"

Adherencija bolesnika pri liječenju šećerne bolesti u obiteljskoj medicini u Republici Hrvatskoj prema istraživanju EUROASPIRE V

Authors: KOVAČEC, LOVORKA CEROVEČKI, VENIJA KERMC, INO et al.

Source: Liječnički vjesnik, Vol 147, Iss 1-2, Pp 22-29 (2025)
Liječnički vjesnik
CODEN LIVJA5
Volume 147
Issue 1-2

Subject Terms: Medicine (General), HYPOGLYCEMIC AGENTS – therapeutic use, CROATIA – epidemiology, medication adherence – statistics and numerical data, MEDICATION ADHERENCE – statistics and numerical data, ANKETE I UPITNICI, DIABETES MELLITUS, TYPE 2 – drug therapy, epidemiology, R5-920, PRIDRŽAVANJE LIJEČENJA – statistički podatci, hypoglycemic agents – therapeutic use, OBITELJSKA MEDICINA – statistički podatci, PATIENT COMPLIANCE – statistics and numerical data, patient compliance – statistics and numerical data, Diabetes mellitus, type 2 – drug therapy, epidemiology, ŠEĆERNA BOLEST TIPA 2 – epidemiologija, farmakoterapija, life style, SURADLJIVOST BOLESNIKA – statistički podatci, family practice – statistics and numerical data, SURVEYS AND QUESTIONNAIRES, FAMILY PRACTICE – statistics and numerical data, HIPOGLIKEMICI – terapijska uporaba, surveys and questionnaires, LIFE STYLE, NAČIN ŽIVOTA, Croatia – epidemiology, HRVATSKA – epidemiologija

File Description: application/pdf

Access URL: https://doaj.org/article/b296a8d5f8414e9e825511f3a6bd80e2
https://urn.nsk.hr/urn:nbn:hr:105:187749
https://doi.org/10.26800/lv-147-1-2-2
https://hrcak.srce.hr/328779
https://doi.org/10.26800/LV-147-1-2-2
https://hrcak.srce.hr/328779
https://doi.org/10.26800/lv-147-1-2-2

Evaluation of important human CYP450 isoforms and P‐glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail

Authors: Neyshaburinezhad, Navid Shirzad, Nooshin Rouini, Mohammadreza et al.

Source: Basic & Clinical Pharmacology & Toxicology. 132:485-497

Subject Terms: 0301 basic medicine, ATP Binding Cassette Transporter, Subfamily B, Genotype, Cytochrome P-450 CYP3A / genetics, Cytochrome P-450 Enzyme System / metabolism, Cytochrome P-450 CYP3A / metabolism, Cytochrome P-450 CYP2C9 / metabolism, 03 medical and health sciences, Cytochrome P-450 Enzyme System, ATP Binding Cassette Transporter, Subfamily B / genetics, Humans, Cytochrome P-450 CYP3A, Protein Isoforms, ATP Binding Cassette Transporter, Subfamily B, Member 1, Cytochrome P-450 CYP2C9, Inflammation, 0303 health sciences, CYP450 phenotype and genotype, Protein Isoforms / metabolism, Type 2 diabetes, Personalized medicine, 3. Good health, Phenoconversion, Cytochrome P-450 Enzyme System / genetics, ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics, Phenotype, Diabetes Mellitus, Type 2, Protein Isoforms / genetics, Cytochrome P-450 CYP2C9 / genetics, Diabetes Mellitus, Type 2 / drug therapy

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/36734157

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

Authors: Østergaard, Helena Bleken Humphreys, Valerie Hengeveld, Ellen Margo et al.

Source: Diabetes Obes Metab

Subject Terms: Antidiabetic drug, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, 03 medical and health sciences, 0302 clinical medicine, Hypoglycemic Agents / therapeutic use, Risk Factors, Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2 / complications, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1 / therapeutic use, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases / epidemiology, Diabetes Mellitus, Type 2 / epidemiology, SGLT2 inhibitor, Type 2 diabetes, Glucose / therapeutic use, Glucagon-Like Peptide-1 Receptor / agonists, Original Articles, Cardiovascular Diseases / chemically induced, Cardiovascular disease, 3. Good health, Cross-Sectional Studies, Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Heart Disease Risk Factors, GLP-1, Diabetes Mellitus, Type 2 / drug therapy, Cardiovascular Diseases / prevention & control

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/36199242

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group

Authors: Janez, Andrej Muzurovic, Emir Stoian, Anca Pantea et al.

Source: International Journal of Cardiology. 365:8-18

Subject Terms: Glucagon-Like Peptide 1 / metabolism, Diabetes Mellitus, Type 2* / epidemiology, 03 medical and health sciences, 0302 clinical medicine, Hypoglycemic Agents / therapeutic use, Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2* / diagnosis, Diabetes Mellitus, Type 2* / drug therapy, Liraglutide / therapeutic use, Cardiovascular Diseases* / epidemiology, Humans, Hypoglycemic Agents, Type 2 diabetes mellitus, Liraglutide / pharmacology, GLP-1 receptor agonists, Glucagon-Like Peptide-1 Receptor / agonists, Cardiovascular Diseases* / drug therapy, Liraglutide, Algorithm, Cardiovascular outcomes trials, Treatment, 3. Good health, Hypoglycemic Agents / pharmacology, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Algorithm, Cardiovascular outcomes trials, GLP-1 receptor agonists, Treatment, Type 2 diabetes mellitus, HCC END

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35905827
http://hdl.handle.net/10400.17/4835

Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy

Authors: Dimnjaković, Jelena Buble, Tamara Ivanko, Pero et al.

Source: Sci Rep
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)

Subject Terms: diabetes mellitus type 2, dipeptidyl-peptidase 4 inhibitors, insulin, Substances, COVID-19 Vaccines, Science, hypoglycemic agents, COVID-19 Vaccines / therapeutic use, Cardiomyopathies / chemically induced, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, Article, 03 medical and health sciences, Diabetes mellitus type 2, 0302 clinical medicine, Hypoglycemic agents, Hypoglycemic Agents / therapeutic use, Sodium-glucose transporter 2 inhibitors, sodium-glucose transporter 2 inhibitors, Diabetes Mellitus, Type 2 / complications, pioglitazone, Humans, Hypoglycemic Agents, Insulin, Sulfonylurea Compounds / therapeutic use, Sodium-Glucose Transporter 2 Inhibitors, COVID-19 / complications, Retrospective Studies, repaglinide, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2 / epidemiology, SARS-CoV-2, COVID-19, Dipeptidyl-Peptidase IV Inhibitors / therapeutic use, Insulin / therapeutic use, 3. Good health, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, Dipeptidyl-peptidase 4 inhibitors, sulfonylurea compounds, Medicine, Diabetes Mellitus, Type 2 / drug therapy, metformin, Cardiomyopathies, acarbose

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38538694
https://doaj.org/article/ccd5faca0b2744be8ccf749fe414a26a

Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis

Authors: David Beran Jennifer Manne-Goehler Demetre Labadarios et al.

Contributors: David Beran Jennifer Manne-Goehler Demetre Labadarios et al.

Source: The Lancet Diabetes & Endocrinology. 9:825-836

Subject Terms: Blood Glucose, Heart Failure, Diabetes Mellitus, Type 2 / epidemiology, Cost-Benefit Analysis, 1. No poverty, Insulin Glargine, Glucagon-Like Peptide-1 Receptor / agonists, Insulin / therapeutic use, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents / therapeutic use, Blood Glucose / metabolism, Humans, Hypoglycemic Agents, Insulin, Insulin Glargine / therapeutic use, Diabetes Mellitus, Type 2 / drug therapy, Developing Countries, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure / drug therapy

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/34656210
https://research.birmingham.ac.uk/portal/en/publications/expanding-access-to-newer-medicines-for-people-with-type-2-diabetes-mellitus-in-low-and-middleincome-countries(80562337-34e7-4c4d-be07-c75e6ea2ef0e).html

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Authors: Gregory G. Schwartz Michael Szarek Vera A. Bittner et al.

Contributors: Gregory G. Schwartz Michael Szarek Vera A. Bittner et al.

Source: Diabetes Care
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Subject Terms: Cardiovascular and Metabolic Risk, Type 2* / epidemiology Double-Blind Method Humans Lipoprotein(a) Proprotein Convertase 9 Treatment Outcome, Anticholesteremic Agents, Antibodies, Monoclonal, Humanized, Antibodies, 3. Good health, 03 medical and health sciences, Type 2* / drug therapy Diabetes Mellitus, Treatment Outcome, 0302 clinical medicine, Diabetes Mellitus, Type 2, Double-Blind Method, Humanized Anticholesteremic Agents* Diabetes Mellitus, Monoclonal, Diabetes Mellitus, Humans, Proprotein Convertase 9, Humanized, Type 2, Antibodies, Monoclonal, Humanized Anticholesteremic Agents* Diabetes Mellitus, Type 2* / drug therapy Diabetes Mellitus, Type 2* / epidemiology Double-Blind Method Humans Lipoprotein(a) Proprotein Convertase 9 Treatment Outcome, Lipoprotein(a)

File Description: application/pdf

Access URL: https://figshare.com/articles/figure/Relation_of_Lipoprotein_a_Levels_to_Incident_Type_2_Diabetes_and_Modification_by_Alirocumab_Treatment/13805825/1/files/26750645.pdf
https://care.diabetesjournals.org/content/diacare/44/5/1219.full.pdf
https://escholarship.org/content/qt5h6931kv/qt5h6931kv.pdf?t=qq3qeq
https://pubmed.ncbi.nlm.nih.gov/33722880
https://hdl.handle.net/20.500.12530/59518
https://escholarship.org/uc/item/5h6931kv
https://www.ncbi.nlm.nih.gov/pubmed/33722880
https://researchnow.flinders.edu.au/en/publications/relation-of-lipoproteina-levels-to-incident-type-2-diabetes-and-m
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132323
https://escholarship.org/content/qt5h6931kv/qt5h6931kv.pdf?t=qq3qeq
http://care.diabetesjournals.org/content/early/2021/03/10/dc20-2842
https://hdl.handle.net/1887/3274114
https://escholarship.org/uc/item/5h6931kv

Inhibiteurs du SGLT2 : que des bénéfices ?

Authors: Sciotto, Lucie Jornayvaz, François

Source: Revue Médicale Suisse. 17:1072-1077

Subject Terms: Inhibiteur, 03 medical and health sciences, 0302 clinical medicine, Urinary Tract Infections, Hypoglycemic Agents / adverse effects, Humans, Ketosis, Diabetes Mellitus, Type 2 / drug therapy, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, Diabète de type 2, Amputation, Surgical

File Description: application/pdf

Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires

Authors: Lu, Henri Hullin, Roger Yerly, Patrick et al.

Source: Revue Médicale Suisse. 17:1034-1038

Subject Terms: Benzhydryl Compounds / adverse effects, Heart Failure, 03 medical and health sciences, 0302 clinical medicine, Hypoglycemic Agents / adverse effects, Humans, Stroke Volume, Cardiovascular Diseases / chemically induced, Diabetes Mellitus, Type 2 / drug therapy, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

File Description: application/pdf

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline

Authors: Agarwal, Arnav Zeng, Xiaoxi Li, Sheyu et al.

Source: BMJ. :e080257

Subject Terms: Adult, Renal Insufficiency, Chronic / complications, Hypoglycemic Agents / adverse effects, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, Sodium-Glucose Transporter 2 Inhibitors / adverse effects, Diabetes Mellitus, Type 2, Hypoglycemic Agents / therapeutic use, Cardiovascular Diseases, Disease Progression, Diabetes Mellitus, Type 2 / complications, Humans, Hypoglycemic Agents, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 / drug therapy, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases / prevention & control

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39353639

Acute Esophageal Necrosis as a Rare Complication of Metabolic Acidosis in a Diabetic Patient: A Case Report

Authors: Greco, Salvatore Giovine, Antonio Rocchi, Cindy et al.

Source: Am J Case Rep

Subject Terms: Male, Necrosis, Diabetes Mellitus, Type 2, Acute Disease, Humans, Articles, Middle Aged, Acidosis, Esophageal Diseases, Esophageal Perforation, Esophagus, Diabetes Mellitus, Type 2* / drug therapy, Esophageal Diseases* / diagnosis, Esophageal Diseases* / etiology

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37580902
https://hdl.handle.net/11392/2527030
https://doi.org/10.12659/AJCR.939624
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437081/

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study

Authors: Bukvić Mokos, Zrinka Petković, Mikela Balić, Anamaria et al.

Source: Croat Med J
Croatian Medical Journal
CODEN CMEJEN
Volume 61
Issue 3
Issue 2

Subject Terms: Pemphigoid, Bullous / epidemiology, Dipeptidyl-Peptidase IV Inhibitors, Bullous pemphigoid, Croatia, Dipeptidyl-Peptidase IV Inhibitors / adverse effects, Pemphigoid, Bullous / chemically induced, Dipeptidyl-Peptidase IV Inhibitors / therapeutic use, 3. Good health, Eosinophils, 03 medical and health sciences, Elderly, 0302 clinical medicine, Diabetes Mellitus, Type 2, Dipeptidyl peptidase-4 inhibitors, Pemphigoid, Bullous, Diabetes Mellitus, Type 2 / complications, Autoimmune blistering diseases, Humans, Diabetes Mellitus, Type 2 / drug therapy, Research Article, Retrospective Studies

File Description: application/pdf

Access URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230411/pdf/CroatMedJ_61_0093.pdf
https://pubmed.ncbi.nlm.nih.gov/32378375
https://www.bib.irb.hr/1104819
https://doi.org/10.3325/cmj.2020.61.93
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230411/
https://doi.org/10.3325/cmj.2020.61.93
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230411/
https://repozitorij.unizg.hr/islandora/object/mef:2552/datastream/FILE0/download
https://repozitorij.mef.unizg.hr/islandora/object/mef:2552/datastream/FILE0/download
https://hrcak.srce.hr/file/348608
https://pubmed.ncbi.nlm.nih.gov/32378375/
https://repozitorij.mef.unizg.hr/islandora/object/mef%3A2552
https://hrcak.srce.hr/253120
https://doi.org/10.3325/cmj.2020.61.93
https://hrcak.srce.hr/file/367825
https://hrcak.srce.hr/253120
https://doi.org/10.3325/cmj.2020.61.93
https://hrcak.srce.hr/file/348608
https://hrcak.srce.hr/240160
https://doi.org/10.3325/cmj.2020.61.93
https://hrcak.srce.hr/240160
https://doi.org/10.3325/cmj.2020.61.93

Diabétologie

Authors: Jornayvaz, François Gariani, Karim

Source: Revue médicale suisse, Vol. 17, No 723 (2021) pp. 188-191
Revue médicale suisse, Vol. 16, No 676-7 (2020) pp. 31-33

Subject Terms: ddc:616, Diabétologie, Diabetes Mellitus, Type 2 / epidemiology, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, Inhibiteurs du SGLT2, Analogue du GLP-1, Hypoglycemic Agents/therapeutic use, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, Glucagon-Like Peptide-1 Receptor, Metformin, 3. Good health, Hypoglycemic Agents / therapeutic use, General Practitioners, Diabetes Mellitus, Humans, Diabetes Mellitus, Type 2 / drug therapy, Type 2/drug therapy/epidemiology, Type 2/diagnosis/drug therapy

File Description: application/pdf

Access URL: https://archive-ouverte.unige.ch/unige:154928
https://archive-ouverte.unige.ch/unige:139503
https://archive-ouverte.unige.ch/unige:169205
https://doi.org/10.53738/revmed.2022.18.764-65.21

Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis

Authors: Cigrovski BerkoviĆ, Maja Coppola, Alessandro Sesa, Vibor et al.

Source: World J Gastroenterol

Subject Terms: 0301 basic medicine, Metformin / adverse effects, Neuroendocrine Tumors / pathology, Neuroectodermal Tumors, Primitive / drug therapy, Metformin, Pancreatic Neoplasms, Neuroendocrine Tumors, 03 medical and health sciences, 0302 clinical medicine, Diabetes Mellitus, Type 2, Pancreatic Neoplasms / pathology, Humans, Neuroectodermal Tumors, Primitive, Diabetes Mellitus, Type 2 / drug therapy, Meta-Analysis, Retrospective Studies

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38515954
https://urn.nsk.hr/urn:nbn:hr:105:776537
https://doi.org/10.3748/wjg.v30.i7.759

High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study

Authors: Matthew D. Campbell Drazen Babic Uros Bolcina et al.

Source: Acta Diabetol

Subject Terms: Croatia / epidemiology, Adult, Male, Attitude of Health Personnel, Croatia, Guideline Adherence / standards, Decision Making, Slovenia, Time-to-Treatment, Surveys and Questionnaires, Slovenia / epidemiology, Practice Patterns, Physicians' / statistics & numerical data, Humans, Insulin, Time-to-Treatment / statistics & numerical data, Europe, Eastern, Practice Patterns, Physicians', Bulgaria, Type 2 diabetes mellitus, Hungary, Diabetes Mellitus, Type 2 / epidemiology, Greece / epidemiology, Insulin therapy initiation, Greece, Middle Aged, Insulin / therapeutic use, Hungary / epidemiology, 3. Good health, Clinical inertia, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Europe, Eastern / epidemiology, Guideline Adherence / statistics & numerical data, Original Article, Female, Guideline Adherence, Diabetes Mellitus, Type 2 / drug therapy, Bulgaria / epidemiology

File Description: application/pdf

Access URL: https://link.springer.com/content/pdf/10.1007/s00592-019-01346-1.pdf
https://pubmed.ncbi.nlm.nih.gov/30993528
https://www.bib.irb.hr/1260056
https://doi.org/10.1007/s00592-019-01346-1
https://link.springer.com/article/10.1007/s00592-019-01346-1
https://eprints.whiterose.ac.uk/144886/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675753
https://europepmc.org/article/MED/30993528
https://pubmed.ncbi.nlm.nih.gov/30993528/
https://paperity.org/p/192801660/high-level-of-clinical-inertia-in-insulin-initiation-in-type-2-diabetes-across-central
http://doi.org/10.1007/s00592-019-01346-1

Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes

Authors: Davies, Melanie J. Drexel, Heinz Jornayvaz, François et al.

Source: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-20 (2022)

Subject Terms: Diabetes Mellitus, Type 2 / diagnosis, Cardiovascular Diseases / complications, Heart failure, Review, GLP-1 RAs, Diabetes Mellitus, Type 2 / chemically induced, 03 medical and health sciences, Sodium-Glucose Transporter 2 Inhibitors / adverse effects, 0302 clinical medicine, Cardiovascular safety, Glucagon-Like Peptide 1, Chronic kidney disease, Diseases of the circulatory (Cardiovascular) system, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1 / therapeutic use, Glucose-lowering drug, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure / drug therapy, Heart Failure, Hypoglycemic Agents / adverse effects, Type 2 diabetes, Glucagon-Like Peptide-1 Receptor / agonists, Cardiovascular disease, 3. Good health, Cardiovascular Diseases / diagnosis, Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, CVOTs, Cardiovascular Diseases, RC666-701, Diabetes Mellitus, Type 2 / drug therapy, Cardiovascular outcomes trials, SGLT2 inhibitors, Cardiovascular Diseases / prevention & control

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35927730
https://doaj.org/article/223e2c548e51480bb975e91283c2b62d
https://archive-ouverte.unige.ch/unige:169194
https://doi.org/10.1186/s12933-022-01575-9

Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis

Authors: Jelena Dimnjaković Tamara Buble Pero Ivanko et al.

Source: PLoS One
PLoS ONE, Vol 19, Iss 3 (2024)

Subject Terms: COVID-19 Vaccines, Renal Insufficiency, Chronic / epidemiology, Science, hypoglycemic agents, COVID-19 Vaccines / therapeutic use, Sodium-Glucose Transporter 2 Inhibitors / therapeutic use, COVID-19 / epidemiology, 03 medical and health sciences, 0302 clinical medicine, Piperidines, Hypoglycemic Agents / therapeutic use, Renal Insufficiency, Chronic / drug therapy, Diabetes Mellitus, Type 2 / complications, Metformin / therapeutic use, Humans, Hypoglycemic Agents, Insulin, Sulfonylurea Compounds / therapeutic use, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, COVID-19 / complications, Retrospective Studies, Diabetes Mellitus, Type 2 / epidemiology, Renal Insufficiency, Chronic / complications, SARS-CoV-2, COVID-19, Insulin / therapeutic use, Metformin, 3. Good health, Sulfonylurea Compounds, type 2, Diabetes Mellitus, Type 2, diabetes mellitus, Medicine, Carbamates, Diabetes Mellitus, Type 2 / drug therapy, Research Article

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38536830
https://doaj.org/article/63786898d7d64ac5aefc9fe080779c4a
https://urn.nsk.hr/urn:nbn:hr:105:672948
https://doi.org/10.1371/journal.pone.0301056

DiabeText, a mobile health intervention to support medication taking and healthy lifestyle in adults with type 2 diabetes: Study protocol for a randomized controlled trial

Authors: Zamanillo Campos, Rocío Fiol-deRoque, Maria Antonia Serrano-Ripoll, Maria Jesus et al.

Source: Repisalud
Instituto de Salud Carlos III (ISCIII)
Docusalut
Conselleria de Salut i Consum del Govern de les Illes Balears

Subject Terms: Adult, Glycated Hemoglobin, Text Messaging, Adulto, Ensayos Clínicos Controlados Aleatorios como Asunto, Diabetes Mellitus, Type 2* / psychology, Hemoglobina Glucada, Telemedicine, 3. Good health, Humanos, Estilo de Vida Saludable, Diabetes Mellitus, Type 2, Envío de Mensajes de Texto, Telemedicine* / methods, Diabetes Mellitus, Type 2* / drug therapy, Humans, Healthy Lifestyle, Randomized Controlled Trials as Topic

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37995967
https://hdl.handle.net/20.500.12105/23631
https://hdl.handle.net/20.500.13003/20115

Comparison of anti‐diabetic drug prescribing in children and adolescents in seven European countries

Authors: Mette Nørgaard Helle Kieler Antje Neubert et al.

Source: Neubert, A, Hsia, Y, de Jong-van den Berg, L T, Janhsen, K, Glaeske, G, Furu, K, Kieler, H, Nørgaard, M, Clavenna, A & Wong, I C 2011, 'Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries', British Journal of Clinical Pharmacology, vol. 72, no. 6, pp. 969-77. https://doi.org/10.1111/j.1365-2125.2011.04045.x

Subject Terms: Male, Databases, Factual, type 1 diabetes, Type 1 - drug therapy - epidemiology, DATABASES, 0302 clinical medicine, Physician's Practice Patterns - statistics and numerical data, Insulin - therapeutic use, Prevalence, Insulin, adolescents, UK, Practice Patterns, Physicians', Child, Hypoglycemic Agents - Therapeutic Use, POPULATION, Insulin - Therapeutic Use, 3. Good health, PREVALENCE, Europe, Europe - Epidemiology, Child, Preschool, Female, type 2 diabetes, insulin, Adolescent, oral anti-diabetics, Hypoglycemic Agents - therapeutic use, 03 medical and health sciences, children, Diabetes Mellitus, Humans, Hypoglycemic Agents, COHORT, Diabetes Mellitus, Type 1 - drug therapy - epidemiology, Diabetes Mellitus, Type 2 - Drug Therapy - Epidemiology, Physician's Practice Patterns - Statistics & Numerical Data, TYPE-1, Diabetes Mellitus, Type 2 - drug therapy - epidemiology, Infant, DIABETES-MELLITUS, Type 2 - drug therapy - epidemiology, PHARMACOEPIDEMIOLOGIC RESEARCH, name=SDG 3 - Good Health and Well-being, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, PROJECTIONS

Access URL: https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2011.04045.x
https://pubmed.ncbi.nlm.nih.gov/21689139
https://research.rug.nl/en/publications/ce86db2c-b85d-443e-bdb2-407c6a247afa
https://hdl.handle.net/11370/ce86db2c-b85d-443e-bdb2-407c6a247afa
https://doi.org/10.1111/j.1365-2125.2011.04045.x
https://pure.rug.nl/ws/files/6770140/Neubert2011BrJClinPharmacol.pdf
https://www.rug.nl/research/portal/publications/comparison-of-antidiabetic-drug-prescribing-in-children-and-adolescents-in-seven-european-countries(ce86db2c-b85d-443e-bdb2-407c6a247afa)/export.html
https://research.rug.nl/en/publications/comparison-of-anti-diabetic-drug-prescribing-in-children-and-adol
http://discovery.ucl.ac.uk/1335929/
https://hub.hku.hk/handle/10722/165618
https://moh-it.pure.elsevier.com/en/publications/comparison-of-anti-diabetic-drug-prescribing-in-children-and-adol
http://hdl.handle.net/10722/165618
http://hdl.handle.net/10722/171433

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Authors: Shi, Qingyang Nong, Kailei Vandvik, Per Olav et al.

Source: BMJ
The BMJ 381, e074068 (2023). doi:10.1136/bmj-2022-074068

Subject Terms: Adult, Heart Failure, Research, Network Meta-Analysis, Mineralocorticoid Receptor Antagonists / adverse effects, Glucagon-Like Peptide-1 Receptor / therapeutic use, Glucagon-Like Peptide-1 Receptor, 3. Good health, Sodium-Glucose Transporter 2 Inhibitors / adverse effects, Diabetes Mellitus, Type 2, Quality of Life, Humans, Kidney Failure, Chronic, Diabetes Mellitus, Type 2 / drug therapy, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure / drug therapy, Mineralocorticoid Receptor Antagonists, Randomized Controlled Trials as Topic

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37024129
https://archive-ouverte.unige.ch/unige:185766
https://doi.org/10.1136/bmj-2022-074068
https://publications.rwth-aachen.de/record/982060